Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | DRD1 | P21728 | 1/20 | 0.62 |
| ▸ | DRD4 | P21917 | 1/20 | 0.62 |
| ▸ | DRD5 | P21918 | 1/20 | 0.62 |
| ▸ | SYK | P43405 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL4267670 | 0.98 | KDM4E (0.68) | KDM4ETDP1CYP2D6TSHRDRD1 | |
| SCHEMBL4661122 | 0.91 | KDM4E (0.60) | KDM4ETDP1CYP2D6TSHRDRD1 | |
| SCHEMBL14578233 | 0.87 | DRD1 (0.65) | KDM4ETDP1CYP2D6TSHRDRD1 | |
| SCHEMBL13744516 | 0.87 | SMN1; SMN2 (0.66) | KDM4ETDP1CYP2D6TSHRDRD1 | |
| SCHEMBL12661473 | 0.85 | POLB (0.73) | TDP1CYP2D6TSHRDRD1DRD4 | |
| SCHEMBL12058633 | 0.84 | TDP1 (0.74) | KDM4ETDP1CYP2D6DRD1DRD4 | |
| SCHEMBL13963827 | 0.82 | SYK (0.71) | KDM4ETDP1CYP2D6TSHRSYK | |
| SCHEMBL12409038 | 0.82 | SYK (0.71) | KDM4ETDP1CYP2D6TSHRSYK | |
| SCHEMBL13791083 | 0.82 | SYK (0.59) | KDM4ETSHRSYKALDH1A1SMN1; SMN2 | |
| SCHEMBL4024630 | 0.82 | DRD1 (0.71) | KDM4ETDP1DRD1DRD4DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
| WO-2017167183-A1 | DIARYL-Β-LACTAM COMPOUND AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | 复旦大学 | 2017-10-05 | — | — | WO | disclosed |
| WO-2007076161-A2 | COMPOUNDS WITH THERAPEUTIC ACTIVITY | MYRIAD GENETICS, INC (US) | 2007-07-05 | — | — | WO | disclosed |
| EP-0633259-B1 | Sulfonylaminopyrimidines, their preparation and their use as medicine | HOFFMANN LA ROCHE (CH) | 1999-01-13 | — | — | EP | disclosed |
| US-5541186-A | ENDOTHELIN RECEPTOR INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 1996-07-30 | — | — | US | disclosed |
| EP-0633259-A1 | Sulfonylaminopyrimidines, their preparation and their use as medicine | F. HOFFMANN-LA ROCHE AG (CH) | 1995-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | UACA, ADCYAP1R1, ADCY1 | KDM4E 4664/4885TDP1 2510/4885CYP2D6 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.